Share This Author
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
- U. Jeppesen, L. Gram, K. Vistisen, S. Loft, H. Poulsen, K. Brøsen
- MedicineEuropean Journal of Clinical Pharmacology
This investigation confirms that paroxetine and fluxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxettine are moderate inhibitors of CyP2C19 and that fluVoxamine is a potent inhibitor of CYp1A2 in humans in vivo.
Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
The relationship between paroxetine and the sparteine oxidation polymorphism
- S. H. Sindrup, K. Brøsen, B. Zussman
- Medicine, BiologyClinical pharmacology and therapeutics
- 1 March 1992
It is concluded that paroxetine and sparteine metabolism cosegregates, but the interphenotype difference in metabolism was less prominent at steady state than after a single dose, presumably because of saturation of thesparteine oxygenase (CYP2D6) in subjects who were extensive metabolizers.
Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms
- S. H. Sindrup, K. Brøsen, M. G. Hansen, T. Aaes-Jørgensen, K. Overø, L. Gram
- Chemistry, BiologyTherapeutic drug monitoring
- 1 February 1993
It was shown that the citalopram elimination partially depends on the mephenytoin oxygenase, since steady-state serum concentration, half-life, and area under the serum concentration/time curve for cITALopram were significantly higher in poor metabolizers of mephenYtoin than in extensive metabolizer of me Pheny toin.
The hypoalgesic effect of tramadol in relation to CYP2D6 *
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
- Mette Marie H. Christensen, C. Brasch-Andersen, K. Brøsen
- MedicinePharmacogenetics and genomics
- 1 December 2011
In a large cohort of type 2 diabetics, an enormous (80-fold) variability in trough steady-state metformin plasma concentration is confirmed and OCT1 genotype has a bearing on HbA1c during meetformin treatment.
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism
It is indicated that the enzyme responsible for a high‐affinity saturable paroxetine elimination process is identical with CYP2D6, the source of the sparteine oxidation polymorphism.
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide
- Tanja Busk Bidstrup, N. Stilling, P. Damkier, B. Scharling, M. Thomsen, K. Brøsen
- Biology, MedicineEuropean Journal of Clinical Pharmacology
- 19 March 2004
The results suggest that concomitant administration of rifampicin and repaglinide may cause a clinically relevant decrease in the glucose-lowering effect of repaglinside, in particular when rifampsicin treatment is discontinued or if the drugs are not administered simultaneously or within a few hours of each other.
Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial